Unknown

Dataset Information

0

Quantitative proteomic analysis reveals that Luks-PV exerts antitumor activity by regulating the key proteins and metabolic pathways in HepG2 cells.


ABSTRACT: Hepatocellular carcinoma (HCC) is a complicated and poor prognosis cancer, necessitating the development of a potential treatment strategy. In this study, we initially revealed that LukS-PV belonged to leukocidin family performs an anti-HCC action. Then, we used liquid chromatography-mass spectrometry (LC/MS) to compare protein expression profiles of the LukS-PV-treated human HCC cell lines HepG2 and the control cells. GO annotations and Kyoto Encyclopedia of Genes and Genomes pathway analysis were carried out of differential expression followed by protein-protein interactome, to explore the underlying cancer suppressor mechanisms of LukS-PV for human HCC. A total of 88 upregulated proteins and 46 downregulated proteins were identified. The top 10 proteins identified by the MCC method are FN1, APP, TIMP1, nucleobindin-1, GOLM1, APLP2, CYR61, CD63, ENG, and CD9. Our observation on protein expression indicated that LukS-PV produces a signature affecting central carbon metabolism in cancer, galactose metabolism, and fructose and mannose metabolism pathways. The results give a functional effects and molecular mechanism insight, following LukS-PV treatment.

SUBMITTER: Zhao CC 

PROVIDER: S-EPMC7028286 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Quantitative proteomic analysis reveals that Luks-PV exerts antitumor activity by regulating the key proteins and metabolic pathways in HepG2 cells.

Zhao Chang-Cheng CC   Yu Wen-Wei WW   Qi Ying-Jie YJ   Xu Liang-Fei LF   Wang Zi-Ran ZR   Qiang Ya-Wen YW   Ma Fan F   Ma Xiao-Ling XL  

Anti-cancer drugs 20200301 3


Hepatocellular carcinoma (HCC) is a complicated and poor prognosis cancer, necessitating the development of a potential treatment strategy. In this study, we initially revealed that LukS-PV belonged to leukocidin family performs an anti-HCC action. Then, we used liquid chromatography-mass spectrometry (LC/MS) to compare protein expression profiles of the LukS-PV-treated human HCC cell lines HepG2 and the control cells. GO annotations and Kyoto Encyclopedia of Genes and Genomes pathway analysis w  ...[more]

Similar Datasets

| S-EPMC9175482 | biostudies-literature
| S-EPMC3870988 | biostudies-literature
| S-EPMC10250288 | biostudies-literature
| S-EPMC8078626 | biostudies-literature
| S-EPMC8565356 | biostudies-literature
| S-EPMC8565650 | biostudies-literature
| S-EPMC4569305 | biostudies-literature
| S-EPMC8584245 | biostudies-literature
| S-EPMC5059860 | biostudies-literature
| S-EPMC10196575 | biostudies-literature